Vericel Co. (NASDAQ:VCEL – Free Report) – HC Wainwright raised their Q3 2024 earnings estimates for Vericel in a report released on Thursday, November 9th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will earn $0.03 per share for the quarter, up from their previous estimate of $0.02. HC Wainwright currently has a “Buy” rating and a $44.50 target price on the stock. The consensus estimate for Vericel’s current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Vericel’s FY2024 earnings at $0.30 EPS, FY2025 earnings at $0.93 EPS, FY2026 earnings at $1.25 EPS and FY2027 earnings at $1.90 EPS.
Vericel (NASDAQ:VCEL – Get Free Report) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.05. The firm had revenue of $45.58 million during the quarter, compared to the consensus estimate of $45.14 million. Vericel had a negative net margin of 5.54% and a negative return on equity of 5.19%.
Vericel Trading Up 4.6 %
Shares of NASDAQ:VCEL opened at $33.91 on Friday. Vericel has a 12 month low of $20.40 and a 12 month high of $39.90. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -147.43 and a beta of 1.67. The company has a 50-day moving average price of $34.17 and a 200-day moving average price of $34.29.
Institutional Investors Weigh In On Vericel
Hedge funds and other institutional investors have recently bought and sold shares of the business. ExodusPoint Capital Management LP grew its holdings in Vericel by 191.0% in the first quarter. ExodusPoint Capital Management LP now owns 42,546 shares of the biotechnology company’s stock worth $1,247,000 after purchasing an additional 27,923 shares during the period. Los Angeles Capital Management LLC purchased a new stake in shares of Vericel during the second quarter valued at approximately $1,016,000. Citigroup Inc. grew its holdings in shares of Vericel by 3.9% during the first quarter. Citigroup Inc. now owns 109,391 shares of the biotechnology company’s stock valued at $3,207,000 after buying an additional 4,088 shares during the last quarter. MAI Capital Management grew its holdings in shares of Vericel by 3.6% during the second quarter. MAI Capital Management now owns 12,040 shares of the biotechnology company’s stock valued at $452,000 after buying an additional 415 shares during the last quarter. Finally, Summit Creek Advisors LLC grew its holdings in shares of Vericel by 0.8% during the first quarter. Summit Creek Advisors LLC now owns 433,547 shares of the biotechnology company’s stock valued at $12,712,000 after buying an additional 3,567 shares during the last quarter.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.
- Five stocks we like better than Vericel
- 3 Warren Buffett Stocks to Buy Now
- MarketBeat Week in Review – 11/6 – 11/10
- What is ChatGPT Stock? How to Invest in It
- Data giants MongoDB and Snowflake just got upgraded
- Most active stocks: Dollar volume vs share volume
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.